Member Directory - Executive Committee

Primary tabs

Chair: Charles Flexner

Objectives:

Create the scientific and programmatic agenda of LEAP to ensure a balanced and objective resource for those engaged in developing LA/ER agents for treatment and prevention of HIV, TB, and Hepatitis B & C.
Bring a broad representation including academic experts in LA/ER therapeutic drug development, community representatives, and non-governmental organizations (NGO’s) with an interest in supporting this field.
Serve as an honest broker to bridge gaps between academia, regulatory agencies, the pharmaceutical industry, and the community.

Charles W. Flexner, MD flex@jhmi.edu Charles W. Flexner, MD, is the Principal Investigator of the Long Acting/Extended Release Antiretroviral Resource Program (LEAP). Conflict of Interest: Dr. Flexner reports receiving consulting income from Gilead Sciences, Merck, ViiV Healthcare, Janssen, and Theratechnologies. He also serves on a scientific advisory board for Navigen Corporation, and serves on a data safety and monitoring board for Advarra. He is a co-inventor on six issued patents related to long-acting drug delivery technology for HIV treatment and prevention.	Elaine J. Abrams, MD eja1@columbia.edu Dr. Abrams is a Professor of Epidemiology and Pediatrics at Columbia University and Senior Director for Research at ICAP. Conflict of Interest: Has no real or apparent conflicts of interest to report.
Chari Cohen, MPH, DrPH chari.cohen@hepb.org Dr. Cohen is President of the Hepatitis B Foundation, leading national and international efforts to eliminate hepatitis B through developing partnerships, capacity and strategies to improve hepatitis B and D screening, vaccination, and linkage to care. Conflict of Interest: Represents the Hepatitis B Foundation on community advisory boards for Gilead Sciences and GSK; all consulting fees are paid directly to the Hepatitis B Foundation. The Hepatitis B Foundation partners with Clinical Care Options and PeerView on the development, dissemination, and faculty participation for CME courses related to hepatitis B, hepatitis D, and liver cancer, and receives research and program grants from Gilead Sciences, GSK, Vir Biotechnology, Sanofi, Precision BioSciences, GigaGen, Parexel, nChroma, Exact Sciences, Aligos, Mirum, and DiaSorin.	Angela Colbers, PhD a.colbers@cbg-meb.nl Angela Colbers, PhD is a staff researcher at Radboud University Medical Center with expertise in pharmacology and pharmacokinetics in special populations, particularly during pregnancy. She coordinates the international PANNA network and contributes to WHO advisory groups focused on HIV therapeutics in pregnancy and pediatrics. Conflict of Interest: Has no real or apparent conflicts of interest to report.
Lobna Gaayeb, PhD lgaayeb@medicinespatentpool.org Lobna Gaayeb manages the Long-Acting Technologies project at the Medicines Patent Pool. She has experience in coordinating international networks and scientific projects. Conflict of Interest: Has no real or apparent conflicts of interest to report.	Rodney JY Ho, PhD, FAAPS, FAAS rodneyho@uw.edu Dr. Rodney JY Ho is a distinguished professor of pharmaceutics (SOP), adjunct professor of bioengineering (SOM) and is an inaugural presidential entrepreneurial fellow of the University of Washington. Conflict of Interest: No disclosures.
Daniel R. Kuritzkes, MD dkuritzkes@bwh.harvard.edu Daniel R. Kuritzkes, MD received his BS and MS degrees in Molecular Biophysics and Biochemistry from Yale University, and his MD from Harvard Medical School. Receives consulting and/or advisory board fees from Decoy, Gilead, GlaxoSmithKline, Janssen, Merck, Shionogi, and ViiV. Receives non-CME/CE service fees from Gilead.	Imelda Mahaka imahaka@pzat.org Imelda Mahaka is the Executive Director for Pangaea Zimbabwe AIDS Trust (PZAT). She provides strategic direction, overall oversight, coordination, and support for the implementation of PZAT programs. Conflict of Interest:
Adeniyi Olangunju, PhD olagunju@liverpool.ac.uk Adeniyi Olagunju is a Reader in Perinatal Systems Pharmacology at the University of Liverpool and a member of the Centre of Excellence for Long-acting Therapeutics (CELT), where he leads the Perinatal Pharmacology Group. His research aims to improve medicine use during pregnancy and the early postpartum period through the integration of clinical research, PBPK modelling, and human-relevant new approach methodologies. By generating model-informed evidence on drug exposure and safety for mothers, fetuses, and newborns, his work addresses critical evidence gaps that continue to limit clinical guidance and drive off-label medicine use. Conflict of Interest: Has no real or apparent conflicts of interest to report.	Andrew Owen, PhD, FSB aowen@liverpool.ac.uk Andrew Owen is a Professor in the Department of Molecular and Clinical Pharmacology and Director of the Centre of Excellence in Long-acting Therapeutics (CELT; www.liverpool.ac.uk/CELT) at the University of Liverpool. Conflict of Interest: Dr. Owen has reported having potential financial conflicts of interest within the past 12 months, or anticipated within the coming 12 months, with the following entities: Tandem Nano Ltd., Gilead, Assembly Biosciences.
Kimberly Scarsi, PharmD, MS kim.scarsi@unmc.edu Dr. Kimberly Scarsi is a Professor at the University of Nebraska Medical Center’s (UNMC) College of Pharmacy. Conflict of Interest:Receives grant funding from Viiv Healthcare Organon, LLC.	Kimberly Struble, PharmD Kimberly.Struble@fda.hhs.gov Kimberly Struble, PharmD, is a Senior Clinical Team Leader in the Division of Antiviral Products at the Food and Drug Administration. Conflict of Interest: None disclosed.
David Thomas, MD, MPH dthomas@jhmi.edu David Thomas is Director of Infectious Diseases and the Stanhope Bayne-Jones Professor of Medicine at the Johns Hopkins School of Medicine. Conflict of Interest: DSMB-Merck and Rho; Scientific Advisory-Vir.